BMS Deal Activity: 13 Deals Analyzed (2019–2026)

Thirteen deals since July 2019, with aggregate total deal value exceeding $48 billion — that is the scale of BMS's external innovation engine. The pattern is unmistakable: oncology dominance (at least 8 of 13 deals), escalating deal sizes, and a pronounced shift toward earlier-stage co-development structures in 2025–2026. BMS deal activity has moved from opportunistic licensing to systematic platform-building, and the May 2026 announcement of a $15.2 billion, 13-program oncology collaboration confirms the company is operating with a thesis, not a shopping list.

BMS's Deal Portfolio

The concentration is stark. Oncology accounts for the vast majority of BMS deal activity by both count and value. Immunology appears selectively — the $1.5B myasthenia gravis license is notable but isolated. Cardiovascular and hematology, listed as focus areas, show up in earlier deals in the dataset but have clearly taken a back seat to the oncology buildout since 2023.

BMS is not diversifying. They are doubling down. The 2025–2026 vintage of deals reads like a coordinated campaign to own the next generation of oncology modalities: bispecific antibodies (BNT327 at $11.1B TDV), antibody-drug conjugates (BL-B01D1 at $8.4B TDV), engineered cell therapies (CAR-T enhancement at $3.6B TDV), and broad discovery platforms (the 13-program collaboration). This is a company stacking bets across modalities within a single therapeutic area — a strategy that only makes sense if you believe oncology's addressable market is expanding faster than competitors can fill it. They are right. For current oncology benchmarks across the industry, the data confirms this acceleration.

Deal Type Preferences

BMS's preferred deal structures — co-development, license, collaboration, and acquisition — reveal a company that wants operational involvement, not passive royalty streams. The mix skews heavily toward co-development and collaboration, which together represent the majority of recent transactions. Pure acquisitions are rare. The $5B solid tumors deal in July 2025 is the only clean acquisition in the top 10, and even that targeted a Phase 2 asset — not a late-stage, de-risked program.

The average upfront ratio of 37.0% of total deal value is the most revealing metric in BMS's deal profile. For context, large-pharma oncology deals in 2024–2025 have averaged upfronts closer to 25–30% of TDV. BMS is paying above-market upfronts relative to total deal value. This is buyer-aggressive, not buyer-friendly. It signals two things: BMS is competing hard for assets (likely against Merck, Roche, and AstraZeneca in most competitive processes), and they are willing to front-load economics to win deals.

But the 37% average obscures meaningful variance. The May 2026 collaboration carries a $600M upfront against $15.2B TDV — just 3.9%. The BL-B01D1 license was 9.5%. By contrast, the Phase 2 solid tumors acquisition was 30%, and the myasthenia gravis license was 11.7%. The pattern: BMS pays proportionally lower upfronts on platform deals and discovery-stage collaborations, but will pay significantly higher percentages for clinical-stage, de-risked assets. If you are bringing a Phase 2 oncology asset to BMS, expect them to compete on upfront. If you are pitching a discovery platform, expect milestone-heavy structures with modest upfronts. Use the Deal Calculator to benchmark where your asset falls on this spectrum.

Strategic Pattern

Three strategic threads run through BMS's deal activity from 2019 to 2026:

• Replacing Revlimid and Opdivo revenue cliffs with next-generation oncology platforms. Revlimid's LOE and Opdivo's competitive erosion from Keytruda are the existential threats BMS has been managing since the Celgene acquisition. Every major deal since 2023 — BL-B01D1, BNT327, the CAR-T enhancement, the 13-program collaboration — is building the post-Opdivo oncology franchise. These are not gap-fills. They are foundation pours.
• Betting on combination and multi-specific modalities. BNT327 (a PD-L1 x VEGF bispecific at $11.1B TDV), BL-B01D1 (a bispecific ADC at $8.4B TDV), and the immuno-oncology combinations deal all point to a thesis that single-target agents will not win in the next cycle. BMS is building an arsenal of combination-ready assets that can be developed in IO-backbone regimens — exactly the playbook that made Opdivo a $9B+ franchise.
• Accessing China- and ex-US-originated innovation at scale. BL-B01D1 (SICHUAN Baili), the antibody program (lung/breast), and the 13-program collaboration all involve partnerships with companies originating assets outside the traditional US/EU biotech ecosystem. BMS is systematically sourcing from China's ADC and bispecific pipeline — a strategy that carries geopolitical risk but offers access to differentiated molecules at lower upfront cost than competing US-originated assets.

The net result: BMS is assembling the most concentrated next-generation oncology pipeline of any large pharma through external deals. They are not hedging across ten therapeutic areas. They are making a singular, conviction-driven bet that oncology innovation — particularly in bispecifics, ADCs, and engineered cell therapies — will generate the next $20B+ in revenue. The strategic coherence is unusually high for a company of this size.

What This Means If You're Pitching to BMS

If you are a biotech founder or BD lead preparing to approach BMS, here is what the data tells you about your positioning:

• Oncology assets with combination potential are the sweet spot. BMS is not buying standalone assets. They are buying assets that fit into an IO-combination development strategy. If your molecule has a clear mechanistic rationale for combination with PD-1/PD-L1 backbone therapy, you are speaking their language. If it does not, you are a lower priority regardless of clinical data quality.
• Phase 1–2 assets command the best upfront economics. BMS paid $1.5B upfront (30% of TDV) for a Phase 2 solid tumors asset and $800M (9.5%) for the BL-B01D1 Phase 2 license. Phase 1 assets have drawn $175–200M upfronts. Discovery-stage collaborations get large TDVs but small upfronts. Know where you sit on this curve and price accordingly.
• Propose co-development or collaboration structures first. BMS's revealed preference is for deals where they retain development involvement. Pure out-licenses with passive royalty structures are not what this team is optimizing for. Come with a co-development proposal that gives BMS operational control in key territories (especially US) while preserving your economics in ex-US or specific indications.
• Expect pushback on upfront above 15% of TDV for early-stage assets. The 37% average upfront ratio is skewed by clinical-stage deals. For preclinical and Phase 1 assets, BMS has consistently structured deals with upfronts in the 3–12% range of TDV. Do not anchor on the headline average — anchor on stage-matched comps. Run your specific scenario through the Partner Matching engine to see how BMS's offer profile compares to other potential acquirers.
• Novel modalities beat novel targets. BMS's portfolio reveals a preference for new modalities (bispecifics, ADCs, engineered cell therapies) applied to validated biology over novel-target/single-modality plays. If you have a bispecific or ADC against a validated oncology target, you are a higher priority than a first-in-class monoclonal against an unvalidated target — even if the latter has more scientific novelty.

One final note on competitive dynamics: BMS is actively competing with AstraZeneca, Merck, and Roche for the same oncology assets. If you are running a competitive process, BMS will move faster and pay more aggressively on upfront than their 37% average suggests — particularly for differentiated assets in solid tumors. Use that leverage, but understand that BMS will extract value through milestone structure, territory splits, and opt-in rights. The upfront is never the whole story.

See which companies match your asset. The Ambrosia calculator's partner matching engine scores 850+ companies against your asset profile — therapeutic area, modality, stage, and deal structure preferences. Run your asset now to see where BMS ranks relative to the full buyer universe, and whether your deal terms are competitive with current BMS licensing deals in 2026.